Black Diamond Therapeutic...

2.26
-0.20 (-8.13%)
At close: Feb 10, 2025, 12:02 PM
undefined%
Bid 2.26
Market Cap 127.88M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.33
PE Ratio (ttm) -1.7
Forward PE n/a
Analyst Buy
Ask 2.27
Volume 445,779
Avg. Volume (20D) 774,208
Open 2.42
Previous Close 2.46
Day's Range 2.22 - 2.43
52-Week Range 1.91 - 7.66
Beta undefined

About BDTX

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penet...

Industry Biotechnology
Sector Healthcare
IPO Date Jan 31, 2020
Employees 54
Stock Exchange NASDAQ
Ticker Symbol BDTX

Analyst Forecast

According to 4 analyst ratings, the average rating for BDTX stock is "Buy." The 12-month stock price forecast is $15.5, which is an increase of 585.84% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
4 months ago
-5.46%
Black Diamond Therapeutics shares are trading high... Unlock content with Pro Subscription
4 months ago
-12.44%
Black Diamond Therapeutics shares are trading lower. The company presented a poster analyzing real-world treatment outcomes for newly diagnosed non-small cell lung cancer patients with non-classical EGFR mutations at the ESMO Congress 2024